21-hydroxylase deficiency differential diagnosis: Difference between revisions
(Undo revision 1333055 by Mehrian.jafari (talk)) |
|||
Line 9: | Line 9: | ||
==Differentiating congenital adrenal hyperplasia due to 21-hydroxylase deficiency from other diseases== | ==Differentiating congenital adrenal hyperplasia due to 21-hydroxylase deficiency from other diseases== | ||
[[Congenital adrenal hyperplasia]] due to 21-hydroxylase deficiency classic type must be differentiated from diseases that cause [[ambiguous genitalia]]:<ref name="pmid17875484">{{cite journal |vauthors=Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT |title=Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development |journal=Best Pract. Res. Clin. Endocrinol. Metab. |volume=21 |issue=3 |pages=351–65 |year=2007 |pmid=17875484 |doi=10.1016/j.beem.2007.06.003 |url=}}</ref><ref name="pmid10857554">{{cite journal |vauthors=White PC, Speiser PW |title=Congenital adrenal hyperplasia due to 21-hydroxylase deficiency |journal=Endocr. Rev. |volume=21 |issue=3 |pages=245–91 |year=2000 |pmid=10857554 |doi=10.1210/edrv.21.3.0398 |url=}}</ref> | [[Congenital adrenal hyperplasia]] due to 21-hydroxylase deficiency classic type must be differentiated from diseases that cause [[ambiguous genitalia]]:<ref name="pmid17875484">{{cite journal |vauthors=Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT |title=Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development |journal=Best Pract. Res. Clin. Endocrinol. Metab. |volume=21 |issue=3 |pages=351–65 |year=2007 |pmid=17875484 |doi=10.1016/j.beem.2007.06.003 |url=}}</ref><ref name="pmid10857554">{{cite journal |vauthors=White PC, Speiser PW |title=Congenital adrenal hyperplasia due to 21-hydroxylase deficiency |journal=Endocr. Rev. |volume=21 |issue=3 |pages=245–91 |year=2000 |pmid=10857554 |doi=10.1210/edrv.21.3.0398 |url=}}</ref> | ||
{| class="wikitable | {| class="wikitable" | ||
! | !Disease name | ||
! colspan="2" |Laboratory tests | ! colspan="2" |Laboratory tests | ||
!Important clinical findings | !Important clinical findings | ||
Line 81: | Line 81: | ||
|Gestational [[hyperandrogenism]] | |Gestational [[hyperandrogenism]] | ||
| | | | ||
* Maternal serum [[androgen]] concentrations (usually [[testosterone]] and [[androstenedione]]) are high | * Maternal serum [[androgen]] concentrations (usually [[testosterone]] and [[androstenedione]]) are high | ||
* If [[virilization]] is caused by exogenous hormone administration, the values may be low because the offending hormone is usually a synthetic [[steroid]] not measured in assays for [[testosterone]] or other [[androgens]] | * If [[virilization]] is caused by exogenous hormone administration, the values may be low because the offending hormone is usually a synthetic [[steroid]] not measured in assays for [[testosterone]] or other [[androgens]] | ||
| | | | ||
Line 95: | Line 94: | ||
{| class="wikitable" | {| class="wikitable" | ||
! | !Disease name | ||
! | !Steroid status | ||
! | !Other laboratory | ||
! | !Important clinical findings | ||
|- | |- | ||
|Non-classic type of 21-hydroxylase deficiency | |Non-classic type of 21-hydroxylase deficiency | ||
| | |Increased: | ||
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | * [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | ||
* Exaggerated [[Androstenedione]], [[DHEA]], and [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | * Exaggerated [[Androstenedione]], [[DHEA]], and [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | ||
response to ACTH | response to [[ACTH]] | ||
| | | | ||
* Low [[testosterone]] levels | * Low [[testosterone]] levels | ||
Line 117: | Line 112: | ||
|- | |- | ||
|[[11β-hydroxylase deficiency|11-β hydroxylase deficiency]] | |[[11β-hydroxylase deficiency|11-β hydroxylase deficiency]] | ||
| | |Increased: | ||
* | * DOC | ||
* 11-Deoxy-[[ | * 11-Deoxy-[[Cortisol]] | ||
Decreased: | |||
* [[Cortisol]] | * [[Cortisol]] | ||
* [[Corticosterone]] | * [[Corticosterone]] | ||
* [[Aldosterone]] | * [[Aldosterone]] | ||
| | | | ||
* Low [[testosterone]] levels | * Low [[testosterone]] levels | ||
Line 132: | Line 126: | ||
|- | |- | ||
|3β-Hydroxysteroid Dehydrogenase | |3β-Hydroxysteroid Dehydrogenase | ||
| | |Increased: | ||
* [[DHEA]] | * [[DHEA]] | ||
* [[17-hydroxypregnenolone]] | * [[17-hydroxypregnenolone]] | ||
* [[Pregnenolone]] | * [[Pregnenolone]] | ||
Decreased: | |||
* [[Cortisol]] | * [[Cortisol]] | ||
* [[Aldosterone]] | * [[Aldosterone]] | ||
Line 149: | Line 143: | ||
| | | | ||
* High [[DHEAS]] and [[androstenedione]] levels | * High [[DHEAS]] and [[androstenedione]] levels | ||
| | | | ||
* Low [[testosterone]] levels | * Low [[testosterone]] levels | ||
Line 161: | Line 154: | ||
| | | | ||
* Variable levels depends on [[tumor]] type | * Variable levels depends on [[tumor]] type | ||
| | | | ||
* Low [[testosterone]] level | * Low [[testosterone]] level | ||
Line 171: | Line 163: | ||
| | | | ||
* Variable levels depends on [[tumor]] type | * Variable levels depends on [[tumor]] type | ||
| | | | ||
* [[Testosterone]] is high | * [[Testosterone]] is high | ||
Line 182: | Line 173: | ||
* Increase [[cortisol]] & metabolites | * Increase [[cortisol]] & metabolites | ||
* Variable other [[steroids]] | * Variable other [[steroids]] | ||
| | | | ||
* Variable [[mineralocorticoid]] excess | * Variable [[mineralocorticoid]] excess | ||
Line 191: | Line 181: | ||
| | | | ||
* Normal levels of most of [[steroids]] | * Normal levels of most of [[steroids]] | ||
| | | | ||
* Increased [[prolactin]] | * Increased [[prolactin]] |
Revision as of 14:26, 1 August 2017
21-hydroxylase deficiency Microchapters |
Differentiating 21-Hydroxylase Deficiency from other Diseases |
Diagnosis |
Treatment |
Case Studies |
21-hydroxylase deficiency differential diagnosis On the Web |
American Roentgen Ray Society Images of 21-hydroxylase deficiency differential diagnosis |
21-hydroxylase deficiency differential diagnosis in the news |
Risk calculators and risk factors for 21-hydroxylase deficiency differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Mehrian Jafarizade, M.D [2]
Overview
21-hydroxylase deficiency must be differentiated from 11-β hydroxylase deficiency, 17-α hydroxylase deficiency, androgen insensitivity syndrome, 3β-Hydroxysteroid Dehydrogenase, polycystic ovarian syndrome, hyperprolactinemia, cushing syndrome, and adrenal tumor.
Differentiating congenital adrenal hyperplasia due to 21-hydroxylase deficiency from other diseases
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency classic type must be differentiated from diseases that cause ambiguous genitalia:[1][2]
Disease name | Laboratory tests | Important clinical findings | |
---|---|---|---|
Increased | Decreased | ||
Classic type of 21-hydroxylase deficiency |
|
| |
11-β hydroxylase deficiency |
|
| |
17-α hydroxylase deficiency |
| ||
3β-Hydroxysteroid Dehydrogenase |
| ||
Gestational hyperandrogenism |
|
|
21-hydroxylase deficiency Non-classic type must be differentiated from diseases that cause virilization and hirsutism in female:[3][2][4]
Disease name | Steroid status | Other laboratory | Important clinical findings |
---|---|---|---|
Non-classic type of 21-hydroxylase deficiency | Increased:
response to ACTH |
|
|
11-β hydroxylase deficiency | Increased:
Decreased: |
|
|
3β-Hydroxysteroid Dehydrogenase | Increased:
Decreased: |
|
|
Polycystic ovary syndrome |
|
|
|
Adrenal tumors |
|
|
|
Ovarian virilizing tumor |
|
|
|
Cushing's syndrome |
|
| |
Hyperprolactinemia |
|
|
References
- ↑ Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT (2007). "Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development". Best Pract. Res. Clin. Endocrinol. Metab. 21 (3): 351–65. doi:10.1016/j.beem.2007.06.003. PMID 17875484.
- ↑ 2.0 2.1 White PC, Speiser PW (2000). "Congenital adrenal hyperplasia due to 21-hydroxylase deficiency". Endocr. Rev. 21 (3): 245–91. doi:10.1210/edrv.21.3.0398. PMID 10857554.
- ↑ Hohl A, Ronsoni MF, Oliveira M (2014). "Hirsutism: diagnosis and treatment". Arq Bras Endocrinol Metabol. 58 (2): 97–107. PMID 24830586. Vancouver style error: initials (help)
- ↑ Melmed, Shlomo (2016). Williams textbook of endocrinology. Philadelphia, PA: Elsevier. ISBN 978-0323297387.=